KotiRyhmätKeskusteluLisääAjan henki
Etsi sivustolta
Tämä sivusto käyttää evästeitä palvelujen toimittamiseen, toiminnan parantamiseen, analytiikkaan ja (jos et ole kirjautunut sisään) mainostamiseen. Käyttämällä LibraryThingiä ilmaiset, että olet lukenut ja ymmärtänyt käyttöehdot ja yksityisyydensuojakäytännöt. Sivujen ja palveluiden käytön tulee olla näiden ehtojen ja käytäntöjen mukaista.
Hide this

Tulokset Google Booksista

Pikkukuvaa napsauttamalla pääset Google Booksiin.

Ladataan...

Bad Blood: Secrets and Lies in a Silicon Valley Startup

– tekijä: John Carreyrou

Muut tekijät: Katso muut tekijät -osio.

JäseniäKirja-arvostelujaSuosituimmuussijaKeskimääräinen arvioMaininnat
1,7761277,377 (4.29)83
"The full inside story of the breathtaking rise and shocking collapse of a multibillion-dollar startup, by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--"The full inside story of the breathtaking rise and shocking collapse of Theranos--the Enron of Silicon Valley--by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in an early fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at the Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--… (lisätietoja)
Ladataan...

Kirjaudu LibraryThingiin, niin näet, pidätkö tästä kirjasta vai et.

Ei tämänhetkisiä Keskustelu-viestiketjuja tästä kirjasta.

» Katso myös 83 mainintaa

Näyttää 1-5 (yhteensä 127) (seuraava | näytä kaikki)
Scary things in this book:
*Patients were harmed
*The complete lack of ethics by Elizabeth Holmes and Sunny Balwani and those who enabled them
*The pure sloppiness of those in charge, the employees and the board members
*How many investors and board members would invest millions without doing the due diligence to verify their investments--including George Schulz, Rupert Murdoch, Henry Kissinger, and James Mattis. (I guess if you are a billionaire throwing away $100M is fine).
*How companies such as CVS and Safeway could invest millions in a partnership--even changing their store layout to build wellness centers without due diligence. (I always wondered why my Safeway took floor space away to build what looks like a clinic/spa).
*Why there aren't more protections for employee whistleblowers and maybe we've gone too far with NDA protections if it means this type of fraud can go on for years. ( )
  auldhouse | Sep 30, 2021 |
I listened to the audiobook, and I was pretty entertained by the story.
John Carreyrou has done a great job writing the book, the flow of the story is attracting and I only felt bored a few times in the midst of the book, but focusing on what I was hearing the rest of the time.
( )
  mdibaiee | Sep 23, 2021 |
As I write this review, Elizabeth Holmes is on trial in U.S. federal court for fraud—a situation which is entirely unsurprising, having read John Carreyrou's Bad Blood. At its peak, the tech start-up which she once ran, Theranos, was valued at $9bn, but as Carreyrou shows that valuation was based on nothing more than bullshit.

Much has been made in the media about Holmes' wide-eyed stare, artificially deepened voice, and penchant for cosplaying Steve Jobs. Anecdotes about this crop up quite a bit in Bad Blood. What I found much more interesting—and what I wish Carreyrou had hammered home a bit more—was how much the story of Theranos is an indictment of systemic issues. Holmes is fundamentally a fairly boring, run-of-the-mill sociopath—she wants money and adulation and doesn't much care who she has to step on along the way in order to get it.

But most sociopaths don't end up on the cover of Forbes by the time they're 30. The real story here is that Holmes attended a private high school in Texas and dropped out of Stanford; the people she got to know along the way allowed her to get a Who's Who of terrible human beings to invest in her company, including Henry Kissinger, Rupert Murdoch, the Waltons, and Betsy DeVos. Holmes leveraged the prestige of her expensive education and wealthy connections, the greed of those who valued dollar signs more than human lives, and the anti-intellectual narcissism of those who believe that "disruption" is a greater good than expertise and common sense. In 2021—a year when people are choosing to ingest veterinary-grade dewormers and shit their brains out rather than take a free, safe vaccination—this is the part that resonates more deeply than the schadenfreude of it all. ( )
  siriaeve | Sep 4, 2021 |
Absolutely amazing.... I couldn't believe half of the stuff I read and researched it myself. I am stonished at hw could this happen in this era.... ( )
  Douna1980 | Sep 3, 2021 |
This book should go in the true-crime category, since that is what it is. Truly, it's a shocker. You'll never look at the healthcare industry the same way again. Or at lawyers, for that matter. But then, you never really liked lawyers much, did you? ( )
1 ääni booklove54 | Jul 25, 2021 |
Näyttää 1-5 (yhteensä 127) (seuraava | näytä kaikki)
ei arvosteluja | lisää arvostelu

» Lisää muita tekijöitä

Tekijän nimiRooliTekijän tyyppiKoskeeko teosta?Tila
John Carreyrouensisijainen tekijäkaikki painoksetlaskettu
Damron, WillKertojamuu tekijäeräät painoksetvahvistettu
Sinun täytyy kirjautua sisään voidaksesi muokata Yhteistä tietoa
Katso lisäohjeita Common Knowledge -sivuilta (englanniksi).
Kanoninen teoksen nimi
Tiedot englanninkielisestä Yhteisestä tiedosta. Muokkaa kotoistaaksesi se omalle kielellesi.
Alkuteoksen nimi
Teoksen muut nimet
Alkuperäinen julkaisuvuosi
Henkilöt/hahmot
Tiedot englanninkielisestä Yhteisestä tiedosta. Muokkaa kotoistaaksesi se omalle kielellesi.
Tärkeät paikat
Tiedot englanninkielisestä Yhteisestä tiedosta. Muokkaa kotoistaaksesi se omalle kielellesi.
Tärkeät tapahtumat
Tiedot englanninkielisestä Yhteisestä tiedosta. Muokkaa kotoistaaksesi se omalle kielellesi.
Kirjaan liittyvät elokuvat
Tiedot englanninkielisestä Yhteisestä tiedosta. Muokkaa kotoistaaksesi se omalle kielellesi.
Palkinnot ja kunnianosoitukset
Tiedot englanninkielisestä Yhteisestä tiedosta. Muokkaa kotoistaaksesi se omalle kielellesi.
Epigrafi (motto tai mietelause kirjan alussa)
Omistuskirjoitus
Tiedot englanninkielisestä Yhteisestä tiedosta. Muokkaa kotoistaaksesi se omalle kielellesi.
For Molly, Sebastian, Jack, and Francesca
Ensimmäiset sanat
Tiedot englanninkielisestä Yhteisestä tiedosta. Muokkaa kotoistaaksesi se omalle kielellesi.
Tim Kemp had good news for his team.
Sitaatit
Viimeiset sanat
Tiedot englanninkielisestä Yhteisestä tiedosta. Muokkaa kotoistaaksesi se omalle kielellesi.
(Napsauta nähdäksesi. Varoitus: voi sisältää juonipaljastuksia)
Erotteluhuomautus
Julkaisutoimittajat
Kirjan kehujat
Tiedot englanninkielisestä Yhteisestä tiedosta. Muokkaa kotoistaaksesi se omalle kielellesi.
Alkuteoksen kieli
Tiedot englanninkielisestä Yhteisestä tiedosta. Muokkaa kotoistaaksesi se omalle kielellesi.
Kanoninen DDC/MDS
Kanoninen LCC

Viittaukset tähän teokseen muissa lähteissä.

Englanninkielinen Wikipedia

-

"The full inside story of the breathtaking rise and shocking collapse of a multibillion-dollar startup, by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--"The full inside story of the breathtaking rise and shocking collapse of Theranos--the Enron of Silicon Valley--by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in an early fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at the Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--

Kirjastojen kuvailuja ei löytynyt.

Kirjan kuvailu
Yhteenveto haiku-muodossa

Suosituimmat kansikuvat

Pikalinkit

Arvio (tähdet)

Keskiarvo: (4.29)
0.5
1 8
1.5
2 5
2.5 1
3 58
3.5 29
4 229
4.5 58
5 270

Oletko sinä tämä henkilö?

Tule LibraryThing-kirjailijaksi.

 

Lisätietoja | Ota yhteyttä | LibraryThing.com | Yksityisyyden suoja / Käyttöehdot | Apua/FAQ | Blogi | Kauppa | APIs | TinyCat | Perintökirjastot | Varhaiset kirja-arvostelijat | Yleistieto | 163,468,441 kirjaa! | Yläpalkki: Aina näkyvissä